Skip to main content
Medpace Holdings, Inc. logo

Medpace Holdings, Inc. — Investor Relations & Filings

Ticker · MEDP ISIN · US58506Q1094 LEI · 549300H8TYEUVTW14A54 US Professional, scientific and technical activities
Open in API
Filings indexed 858 across all filing types
Latest filing 2023-01-18 Board/Management Inform…
Country US United States of America
Listing US MEDP

About Medpace Holdings, Inc.

https://investor.medpace.com/

Medpace Holdings, Inc. is a scientifically-driven, global, full-service clinical contract research organization (CRO) that provides Phase I-IV clinical development services. The company serves the biotechnology, pharmaceutical, and medical device industries, with a mission to accelerate the development of safe and effective medical therapeutics. Medpace employs a disciplined operating approach that leverages regulatory and therapeutic expertise. Its services include clinical pharmacology, central laboratory, bioanalytical, ECG core lab, and imaging core labs. The company has expertise across major therapeutic areas, including oncology, cardiology, metabolic disease, endocrinology, central nervous system, and anti-viral and anti-infective diseases.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated January 16, 2023, reporting the election of a new director to the Board of Medpace Holdings, Inc. It details the appointment of Dr. Femida H. Gwadry-Sridhar as a Class I director, her background, and compensation details. The key content is about a change in the company's board of directors. There are no financial statements or earnings data, nor is this a report publication announcement or certification. The document fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2023-01-18 English
FORM 4
Director's Dealing
2023-01-18 English
FORM 3
Director's Dealing
2023-01-18 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated December 31, 2022, reporting the resignation of a board member, Thomas C. King, from the Board of Directors of Medpace Holdings, Inc. The key content is about a change in the company's board of directors. There is no financial data or report attached, nor is it an announcement of a report publication. The primary subject is a management/board change, which fits the category of Board/Management Information (MANG). The document length is short (2951 characters), consistent with a typical 8-K reporting a director resignation. Therefore, the correct classification is MANG with high confidence.
2023-01-03 English
FORM 4
Director's Dealing
2022-12-13 English
FORM 4
Director's Dealing
2022-12-13 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.